KEY FIGURES OF THE GALENICA GROUP

in million CHF

2016

2015

Net sales

4,118.4

3,791.6

Vifor Pharma

1,167.0

935.4

Galenica Santé

3,008.9

2'914.9

- Health & Beauty

1,437.0

1'393.3

- Services

2,328.9

2'244.6

- Eliminations Galenica Santé

(757.0)

(723.0)

Corporate and Eliminations

(57.5)

(58.7)

EBITDA

489.1

537.4

EBITDA in % of net sales

11.9 %

14.2 %

EBIT

361.5

450.8

Vifor Pharma

245.2

327.7

Galenica Santé

136.0

128.0

- Health & Beauty

96.2

89.8

- Services

41.4

37.1

- Eliminations Galenica Santé

(1.6)

1.1

Corporate and Eliminations

(19.7)

(4.9)

EBIT in % of net sales

8.8 %

11.9 %

Net profit

323.8

370.0

- Attributable to shareholders of Galenica Ltd.

243.6

301.1

- Share of minority interests

80.2

68.9

 

 

in million CHF

2016

2015

Investment in property, plant and equipment and intangible assets1)

304.6

368.6

Investment in research and development

127.1

88.8

Employees at reporting date (FTE)

7,107

6,421

Cash flow from operating activities

257.9

522.2

Total assets

5,431.5

3,640.0

Shareholders' equity

2,301.0

1,976.2

Equity ratio

42.4 %

54.3 %

Net debt

1,733.5

159.1

Gearing

75.3 %

8.1 %

1)Including upfront and milestone payments from licensing agreements of CHF 218.6 million (previous year: CHF 290.4 million)

Contact

Galenica Ltd.

Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 81 11
Fax:
+41 58 852 81 12

Send link

Send as link



Links

  •